Extrapyramidal syndromes: Epidemiology, pathophysiology and the diagnostic dilemma

CNS Drugs

Volumn 5, Issue SUPPL. 1, 1996, Pages 1-12

  Casey, Daniel E ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMOXAPINE; CLOZAPINE; DOPAMINE; HALOPERIDOL; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PROCHLORPERAZINE; SEROTONIN;

AGING; AKATHISIA; EXTRAPYRAMIDAL SYNDROME; HUMAN; PARKINSONISM; PRIORITY JOURNAL; REVIEW;

EID: 0029780479     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199600051-00003     Document Type: Review

References (62)

1. Deniker P. Introduction of neuroleptic chemotherapy into psychiatry. In: Ayd FJ, Blackwell B, editors. Discoveries in biological psychiatry. Baltimore: Ayd Medical Communications, 1984: 155-64
2. Casey DE, Keepers GA. Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Casey DE, Christensen AV, editors. Psychopharmacology: current trends. Berlin: Springer, 1988: 74-93
3. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983; 40: 1113-7
4. Adler LA, Angrist B, Reiter S, et al. Neuroleptic-induced akathisia: a review. Psychopharmacology 1989; 97: 1-11
5. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054-60
6. Casey DH. Spontaneous and tardive dyskinesias: clinical and laboratory studies. J Clin Psychiatry 1985; 46: 42-7
7. Kane JM, Jeste DV, Barnes TRE, et al. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington DC: American Psychiatric Association, 1992
8. Saltz BL, Woerner M, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266: 2402-6
9. Kane JM, Woerner M, Weinhold P, et al. Incidence of tardive dyskinesia: five year data from a prospective study. Psychopharmacol Bull 1984; 20: 39-40
10. Ganzini L, Heintz R, Hoffman WF, et al. Acute extrapyramidal syndromes in neuroleptic-treated elders: a pilot study. J Geriatr Psychiatry Neurol 1991; 4: 222-5
11. Richardson MA, Haugland G, Craig TJ. Neuroleptic use, parkinsonism-like symptoms, tardive dyskinesia and associated factors in child and adolescent psychiatric patients. Am J Psychiatry 1991; 148: 1322-8
12. Keepers GA, Casey DE. Prediction of neuroleptic-induced dystonia. J Clin Psychopharmacol 1987; 7: 342-4
13. Keepers GA, Casey DE. Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry 1991; 148: 85-9
14. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989; 99: S47-53
15. Cohen BM, Keck PE, Satlin A, et al. Prevalence and seventy of akathisia in patients on clozapine. Biol Psychiatry 1991; 29: 1215-9
16. Kurz M, Hummer M, Oberbauer H, et al. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology 1995; 118 (1): 52-6
17. Peacock L, Solgaard T, Lublin H, et al. Clozapine versus typical antipsychotics: a retro- and prospective study of EPS. Psychopharmacology 1995. In press
18. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151 (6): 825-35
19. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712-26
20. Casey DE, Hansen TE. Schizophrenia Psychopharmacology: risperidone and clozapine. In: Jefferson JW, Griest JH, editors. The psychiatric clinics of North America: annual of drug therapy. Philadelphia: W.B. Saunders, 1995: 119-49
21. Hansen LB, Larsen NE, Vestergard P. Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Psychopharmacology 1981; 74: 306-9
22. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in pharmacological treatment of psychosis. Arch Gen Psychiatry 1988; 45: 79-91
23. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine - relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538-44
24. 11C] raclopride. Psychopharmacology 1992; 107: 23-9
25. 2 dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology 1992; 106: 433-8
26. Casey DE. Tardive dyskinesia and affective disorders. In: Gardos G, Casey DE, editors. Tardive dyskinesia and affective disorders. Washington DC: American Psychiatric Press, 1984: 1-20
27. Ganzini L, Heintz R, Hoffman W, et al. Prevalence of tardive dyskinesia in neuroleptic treated diabetics. Arch Gen Psychiatry 1991; 48: 259-63
28. Woerner MG, Saltz BL, Kane JM, et al. Diabetes and development of tardive dyskinesia. Am J Psychiatry 1993; 150 (6): 966-8
29. Casey DE. Tardive dyskinesia mechanisms and abnormal glucose metabolism. In: Beigel A, editor. Proceedings of IX World Congress of Psychiatry: 1993 Jun 10-12: Rio de Janeiro. World Scientific, 1994
30. Rupniak NMJ, Jenner P, Marsden CD. Acute dystonia induced by neuroleptic drugs. Psychopharmacology 1986; 88: 403-19
31. Lewander T, Westerbergh S, Morrison D. Clinical profile of remoxipride - a combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatr Scand Suppl. 1990; 358: 92-8
32. Gerlach J, Casey DE, Kistrup K, et al. Dopamine D-1 and D-2 receptor functions in acute extrapyramidal syndromes and tardive dyskinesia. In: Belmaker RH, Sandler M, Dahlstrom A, editors. Neurology and neurobiology, Volume 42C. Progress in catecholamine research, Part C: Clinical aspects. New York: Alan R. Liss, Inc., 1988: 1-4
33. 1 receptor antagonist. SCH 23390, in Cebus monkeys withdrawn from previous haloperidol treatment. Psychopharmacology 1993; 112: 389-97
34. 2 (haloperidol) antagonists in drug-naive monkeys. Psychopharmacology 1992; 107: 18-22
35. 1 receptor antagonist. Eur J Pharmacol 1991; 202: 133-4
36. Gerlach J, Hansen L. Effect of chronic treatment with NNC 756, a new D-1 receptor antagonist, or raclopride, a D-2 receptor antagonist, in drug-naive Cebus monkeys: dyslonia, dyskinesia and D-1/D-2 supersensitivity. J Psychopharmacol 1993; 7 (4): 355-64
37. 2 (haloperidol) antagonists in chronic double-blind placebo controlled trial Cebus monkeys. Psychopharmacology 1995; 121: 289-93
38. VanTol HHM, Bunzow JR, Guan H, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-4
39. Snyder S, Greenberg D, Yamamura H. Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 1974; 31:58-61
40. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin pKi values. J Pharmacol Exp Ther 1989; 251: 238-46
41. Casey DE. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology 1994; 112 Suppl.: S55-9
42. Casey DE. Tardive dyskinesia: pathophysiology. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 1497-502
43. Casey DE. Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatr Scand 1994; 89 Suppl. 380: 14-20
44. Barnes TRE, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985; 42: 874-8
45. Villeneuve A. The rabbit syndrome: a peculiar extrapyramidal reaction. Can Psychiatr Assoc J 1972; 17: 69-72
46. Casey DE. The rabbit syndrome. In: Joseph AB, Young R, editors. Disorders of movement in psychiatry and neurology. Cambridge: Blackwell, 1992: 139-42
47. Spohn HE, Strauss ME. Relation of neuroleptic dose and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 1989; 98: 367-80
48. Lewander T. Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand 1994; 89 Suppl. 380: 8-13
49. Waddington JL. Tardive dyskinesia in schizophrenia and other disorders: associations with ageing, cognitive dysfunction and structural brain pathology in relation to neuroleptic exposure. Hum Psychopharm 1987; 2: 11-22
50. Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994; 151 (6): 836-41
51. Levinson DF, Simpson GM, Singh H, et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 1990; 47: 761-8
52. Casey DE. Aspects of motor and mental extrapyramidal syndromes. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 105-14
53. Kaufmann CA, Wyatt RJ. Neuroleptic malignant syndrome. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York; Raven Press, 1987: 1421-30
54. Fleischhacker WW, Miller Ch, Barnas C, et al. The effect of activation procedures on neuroleptic-induced akathisia. Br J Psychiatry 1993; 163: 781-4
55. Gerlach J, Korsgaard S, Clemmesen P, et al. The St. Hans rating scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand 1993; 87: 244-52
56. Chouinard G, Ross-Chouinard A, Annable L. Extrapyramidal symptom rating scale. Can J Neurol Sci 1980; 7: 233
57. Barnes TRF. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-6
58. Fleischhacker WW, Bergmann KL, Perovich R. The Hillside Akathisia Scale: a new rating instrument for neuroleplic-induced akathisia. Psychopharmacol Bull 1989; 25: 222-6
59. Simpson GM, Angus JWS. A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand Suppl 1970; 212: 11-9
60. Caligiuri MP, Lohr JB, Bracha HS, et al. Clinical and instrumental assessment of neuroleptic-induced parkinsonism in patients with tardive dyskinesia. Biol Psychiatry 1991; 29: 139-48
61. Guy W. ECDEU Assessment manual for psychopharmacology, revised 1976. Washington DC: US Government Printing Office, 1976: 534-7
62. BÜchel C, de Leon J, Simpson GM, et al. Oral tardive dyskinesia: validation of a measuring device using digital image processing. Psychopharmacology 1995; 117: 162-5